A 2026 eLife computational study modeled classical psychedelics by increasing a network state variable from alpha = 0 to alpha = 1, shifting perception from bottom-up sensory inference toward top-down generative replay. The result is a useful but still unproven oneirogen model: hallucinations look less like random noise and more like wake-time replay of a …
Psychedelic-assisted therapy has been one of the most-covered mental-health stories of the past decade. A 2026 quantitative analysis by Evers and colleagues maps how media enthusiasm grew, peaked, and partially pulled back across major U.S. outlets — and how the coverage related to the actual evidence base for depression and PTSD.1 Research Highlights Psychedelic clinical …
Media coverage of psychedelics outpaces the trial evidence. MDMA-PTSD signals are large; psilocybin-depression effects shrink against active comparators.
Recent research has provided compelling evidence on the therapeutic potential of psilocybin, a naturally occurring psychedelic, in treating depression. A systematic review and dose-response meta-analysis shed light on the optimal dosage of psilocybin for depression, revealing variations in effectiveness based on patient subgroups and associated risks. Highlights: Psilocybin showed significant antidepressant effects, with optimal dosages …
Psychedelic compounds, long associated with the fringes of medicine and spirituality, are now at the forefront of a radical shift in neurology and psychiatry. Decades of clinical trials have begun to unravel the therapeutic potentials of these substances, revealing promising outcomes in the treatment of various psychiatric disorders. However, a notable gap in this burgeoning …
The emerging research into psilocybin, a classical psychedelic, reveals its significant potential in treating Major Depressive Disorder (MDD). Historically used in spiritual and shamanic practices, psilocybin’s recent clinical studies have opened new avenues in mental health treatment, challenging traditional antidepressants like SSRIs. Highlights: Psilocybin’s Historical & Clinical Relevance: A natural compound used for millennia, recent …
The quest for effective treatments for Major Depressive Disorder (MDD) has taken a revolutionary turn with the exploration of psychedelic compounds. Recent research has evaluated the potential of substances like psilocybin and lisuride, offering new hope for patients unresponsive to traditional antidepressants. Highlights: Traditional Limitations: Standard antidepressants often fail to provide relief for 30% of …